News
IMVT
42.60
+4.08%
1.67
J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)
TipRanks · 2d ago
Immunovant price target raised to $45 from $43 at BofA
TipRanks · 2d ago
Bank of America Securities Sticks to Their Buy Rating for Immunovant (IMVT)
TipRanks · 2d ago
Weekly Report: what happened at IMVT last week (0803-0807)?
Weekly Report · 2d ago
Immunovant Reaffirmed at Buy as IMVT-1402 Trials Advance; $53 Price Target Maintained
TipRanks · 5d ago
Truist Financial Keeps Their Hold Rating on Immunovant (IMVT)
TipRanks · 5d ago
Analysts Are Bullish on Top Healthcare Stocks: Corbus Pharmaceuticals (CRBP), Intellia Therapeutics (NTLA)
TipRanks · 5d ago
Immunovant GAAP EPS of -$0.75 misses by $0.12
Seeking Alpha · 6d ago
Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate
Benzinga · 6d ago
Press Release: Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Dow Jones · 6d ago
Press Release: Immunovant Provides Corporate -2-
Dow Jones · 6d ago
Immunovant's Pipeline Momentum Meets the Reality of a Balance Sheet with Limits
Barchart · 08/05 16:16
Immunovant Q1 2027 Earnings Preview
Seeking Alpha · 08/05 14:45
JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50
Benzinga · 08/04 18:40
J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)
TipRanks · 08/04 14:21
Immunovant price target raised to $50 from $47 at JPMorgan
TipRanks · 08/04 12:35
Weekly Report: what happened at IMVT last week (0727-0731)?
Weekly Report · 08/03 09:20
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy
Seeking Alpha · 07/28 03:09
Weekly Report: what happened at IMVT last week (0720-0724)?
Weekly Report · 07/27 09:21
Insiders Cash Out at Immunovant, Helmerich & Payne, SharkNinja, PBF Energy, Venture Global
TipRanks · 07/25 13:01
More
Webull provides a variety of real-time IMVT stock news. You can receive the latest news about Immunovant Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).